Mark Smith - Teladoc Independent Director
4LL Stock | EUR 9.11 0.39 4.11% |
Director
Dr. Mark Douglas Smith, M.D. is Independent Director of the Company. Dr. Smith is a professor of clinical medicine at the University of California at San Francisco as well as a visiting professor at the School of Public Health at the University of California at Berkeley. He is a boardcertified internist and maintains a clinical practice in HIV care at San Francisco General Hospital. A nationally recognized care delivery and health policy expert, Dr. Smith is current cochair of the Guiding Committee of the Health Care Payment Learning and Action Network, a publicprivate partnership launched by the U.S. Department of Health and Human Services. The group promotes the transition to valuebased payment to improve care quality while lowering costs. From 1996 to 2013, Dr. Smith served as the founding president and CEO of the California Health Care Foundation, an independently endowed philanthropy that works to improve healthcare access and quality for Californians. He helped build the foundation into a nationally recognized leader in delivery system innovation, public reporting of care quality, and applications of new technology in healthcare. Dr. Smith was formerly executive vice president of the Henry J. Kaiser Family Foundation. He was elected to the Institute of Medicine in 2001 and chaired its Committee on the Learning Healthcare System, which produced the landmark 2012 report, Best Care at Lower Cost. He serves on the boards of the Institute for Healthcare Improvement and the Commonwealth Fund and is on the editorial board of Health Affairs since 2018.
Age | 67 |
Tenure | 7 years |
Phone | 203 635 2002 |
Web | https://www.teladochealth.com |
Mark Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Smith against Teladoc stock is an integral part of due diligence when investing in Teladoc. Mark Smith insider activity provides valuable insight into whether Teladoc is net buyers or sellers over its current business cycle. Note, Teladoc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Teladoc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Smith over six months ago Disposition of 2212 shares by Mark Smith of Smith Wesson at 15.21 subject to Rule 16b-3 | ||
Mark Smith over six months ago Acquisition by Mark Smith of 8490 shares of Phreesia subject to Rule 16b-3 | ||
Mark Smith over six months ago Disposition of 28800 shares by Mark Smith of Smith Wesson subject to Rule 16b-3 | ||
Mark Smith over a year ago Payment of 2268 shares by Mark Smith of Smith Wesson subject to Rule 16b-3 |
Teladoc Management Efficiency
The company has return on total asset (ROA) of (0.0129) % which means that it has lost $0.0129 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4885) %, meaning that it generated substantial loss on money invested by shareholders. Teladoc's management efficiency ratios could be used to measure how well Teladoc manages its routine affairs as well as how well it operates its assets and liabilities.Teladoc has accumulated 1.54 B in total debt with debt to equity ratio (D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. Teladoc has a current ratio of 3.88, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Teladoc until it has trouble settling it off, either with new capital or with free cash flow. So, Teladoc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teladoc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teladoc to invest in growth at high rates of return. When we think about Teladoc's use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 1 records | DIRECTOR Age | ||
James McKelvey | Square Inc | 58 |
Management Performance
Return On Equity | -1.49 | |||
Return On Asset | -0.0129 |
Teladoc Leadership Team
Elected by the shareholders, the Teladoc's board of directors comprises two types of representatives: Teladoc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teladoc. The board's role is to monitor Teladoc's management team and ensure that shareholders' interests are well served. Teladoc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teladoc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Goldstein, Independent Director | ||
Mike Waters, Chief Officer | ||
Andrew Turitz, Senior Vice President of Business Development | ||
Catherine Jacobson, Independent Director | ||
Sandra Fenwick, Director | ||
Michelle Bucaria, Chief Human Resource Officer | ||
Christopher Bischoff, Director | ||
David Shedlarz, Independent Director | ||
William Frist, Independent Director | ||
Mala Murthy, Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Controller | ||
Mark Smith, Independent Director | ||
David Snow, Independent Chairman of the Board | ||
David Sides, Chief Operating Officer | ||
Richard Napolitano, Chief VP | ||
Thomas McKinley, Independent Director | ||
Christopher Caridi, Senior Vice President Chief Accounting Officer, Controller | ||
Karen Daniel, Director | ||
Lewis Levy, Chief Medical Officer | ||
Claus Jensen, Chief Officer | ||
Adam Vandervoort, Chief Legal Officer and Secretary | ||
Gabriel Cappucci, Senior Vice President Chief Accounting Officer, Controller | ||
Kenneth Paulus, Independent Director | ||
Stephanie Verstraete, Chief Marketing Officer | ||
George Brooks, CoFounder | ||
Hemant Taneja, Director | ||
Glen Tullman, Director | ||
Helen Darling, Independent Director | ||
CPA CFA, VP Relations | ||
Jason Gorevic, Chief Executive Officer, Director | ||
Courtney McLeod, Director Communication |
Teladoc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teladoc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.49 | |||
Return On Asset | -0.0129 | |||
Operating Margin | (0.09) % | |||
Current Valuation | 5.01 B | |||
Shares Outstanding | 162.84 M | |||
Shares Owned By Insiders | 0.96 % | |||
Shares Owned By Institutions | 82.07 % | |||
Price To Book | 0.75 X | |||
Price To Sales | 1.77 X | |||
Revenue | 2.41 B |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Teladoc Stock
When determining whether Teladoc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teladoc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teladoc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teladoc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Teladoc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Teladoc Stock please use our How to Invest in Teladoc guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.